IL-PRICEFX
12.1.2021 15:32:31 CET | Business Wire | Press release
Pricefx , the global leader in cloud pricing software, today announced another year of tremendous growth during its fiscal year ending December, 31, 2020. Despite a global pandemic and mandatory work-from-home initiatives in every region, the company recorded 44% year-over-year growth in subscription revenue.
This week, Pricefx was named to Built In Chicago’s “Best Places to Work” list , including additional accolades for “Chicago Best Midsize Companies to Work For” and “Chicago Best Paying Companies.” In 2020, Pricefx grew its global headcount by 29% and now employs nearly 400 full time people worldwide, and is currently looking to hire more than 25 new positions in the first quarter of 2021.
“The COVID-19 pandemic forced rapid and transformational changes onto our business in 2020, but this ultimately highlighted the flexibility and resiliency of our incredible team and products,” said Marcin Cichon, Co-Founder and CEO of Pricefx. “I am both impressed by, and deeply grateful for, the passionate dedication our Pricefx family showed this year, enabling us to overcome unprecedented business circumstances to successfully raise significant additional funding, launch innovative new solutions like Lightning and VELO, acquire AI optimization company Brennus Analytics and remain on a rapid growth path with 30 new customers coming on board. I believe our future has never been brighter as I look towards the coming year.”
Market Demand and Customer Wins
In 2020, Pricefx signed 30 new enterprise customers, including Altium Packaging , PLZ Aeroscience , Stahl Holdings B.V. and Verallia Group . The company serves customers in more than 37 countries, which include some of the largest manufacturing, retailing and energy businesses in the world.
To help businesses develop strategies to quickly react to changing market dynamics and challenges as a result of COVID-19, Pricefx offered its customers free access to Sales Insights Accelerator . This Accelerator is a preconfigured, easy to deploy, highly actionable pricing analytics solution that can analyze transactional data, quickly gain visibility into pricing opportunities and flag threats.
In June, Pricefx received $65 million in Series C funding , more than double the amount raised in their previous funding round, bringing the company’s total raised to $130 million. The round was led by funds advised by Apax Digital, the growth equity team of Apax Partners, with participation from existing investor Digital+ Partners. Over the last six months of the year, the company focused the new funding on expanding global market leadership and accelerating product innovation.
Product Innovation
In May 2020, Pricefx acquired Brennus Analytics , a start-up using proprietary AI technology to provide unique optimization capabilities highly applicable to the challenges of complex B2B environments. The transaction allowed Pricefx to incorporate state-of-art AI technology into its price optimization software and bring on a team of exceptionally talented AI and data science professionals.
To that end, Pricefx launched a set of groundbreaking product enhancements in its Vesper release in November 2020. Delivering a more streamlined, powerful and agile pricing platform, the company introduced a sleek, dynamic new look for all of Pricefx’s industry-leading pricing modules with Unity UI; PriceOptimizer AI, a next-generation price optimization solution powered by transparent and predictive machine learning and multi-agent AI; and new pre-defined solution building blocks that quickly and easily incorporate best practice functionality.
Earlier in the year, Pricefx announced Lightning , the first turnkey solution to enable rapid activation of pricing excellence. Powered by Pricefx Accelerators, Lightning delivers a full suite of standard pricing analytics, management and CPQ realization tools, able to go live in six weeks or less. This was followed by a partnership with Bain & Company to launch three advanced pricing Accelerators to help Bain customers address frontline discounting, pricing leakage and promotion management.
Most recently, Pricefx introduced Velo , the industry’s first strategic large deal negotiation solution. Designed for large, complex deals, Velo maximizes profitability and leverage by combining proven strategy with innovative technology.
Awards and Accolades
In December, Tracxn included Pricefx in its Soonicorn Club of Germany which recognizes the top companies which have the potential to become Unicorns. As a Soonicorn, Pricefx has been placed amongst the leading tech startups of Germany. The rating is based on a detailed analysis by Tracxn internal sector specialist teams coupled with a combination of multiple publicly available signals such as market size, investment by marquee investors, execution excellence and future growth prospects.
Over the last 12 months, Pricefx products were also honored for innovation and customer traction. The 2020 SaaS Awards Program named Pricefx the Best SaaS for Sales and Marketing and the company took the Gold Stevie® Award for the manufacturing solution category in the 2020 International Business Awards. Pricefx was named the Bronze Stevie® Award winner in the 2020 American Business Awards for best cloud application/service.
The innovative Pricefx offering continued to garner attention from the global industry analyst community, earning them inclusion in the Gartner Magic Quadrant for CPQ for the second year in a row. Gartner included Pricefx in more than a dozen research reports, analyst notes and Hype Cycle reports, covering topics including AI and data science, pricing optimization, sales and CRM, and sales execution.
Pricefx remained in the leader quadrant on both the Pricing and Momentum G2 Grids for all four quarters of the year. The company has been reviewed by more than 50 verifed customers on the G2 platform to date. In 2020, Pricefx continued to make the Constellation ShortList ™ for Price Optimization.
Demonstrating a strong partnership with SAP, Pricefx was a 2020 SAP® Pinnacle Award finalist for SAP App Center Partner of the Year . Finalists and winners in 34 categories were chosen based on recommendations from the SAP field, customer feedback and performance indicators. Additionally, its Optimized Dynamic Pricing (ODP) solution became an SAP endorsed app, a new category of solutions from SAP’s partner ecosystem to help customers become best-run, intelligent enterprises.
Follow Pricefx
Blog: https://www.pricefx.com/site/blog/
Twitter: https://twitter.com/price_fx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to hundreds of global customers in more than 40 countries worldwide. For more information, please visit www.pricefx.com .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom